- MDClone recently announced it raised $63 million in Series C funding. These are the details.
Digital health company MDClone recently announced a $63 million Series C round of funding, led by two new investors Warburg Pincus, a leading global growth investor, and Viola Growth, Israel’s leading growth fund, with participation from existing investors aMoon, Lightspeed Venture Partners, and OrbiMed.
MDClone is known for providing clinicians and healthcare professionals with the ability to explore healthcare data independently and without barriers. And the MDClone ADAMS Platform is a powerful data analytics environment, encouraging self-service data exploration and action across teams in a healthcare ecosystem – resulting in operational efficiencies, revenue growth, and proactive care for patients around the world.
With this round of funding, MDClone plans to accelerate the expansion of its transformative healthcare data solutions by investing in new regional markets, continuing to develop the existing platform and expanding into new vertical markets including Life Science and Real World Evidence (RWE). And the company will also be hiring a number of key roles as it looks to continue to advance data access and accelerate the power of self-service data exploration.
MDClone has seen strong demand for its data platform including synthetic data capabilities with revenues more than doubling over the past year thanks to new customers in the U.S. and Canada. And serving major health systems, federal agencies including the VA and NIH, and academic research organizations, MDClone continues to grow and is focused on new regions including Asia Pacific, Europe, and the Middle East.
KEY QUOTES:
“Our mission from the start was to help the healthcare ecosystem use data to improve care delivery and health. Through our journey, we’ve seen great examples around the world where innovation, passion, and technology combine to drive better outcomes. With our technology and growing customer base, we are focused on continuing our global mission and are excited to accelerate the development of new capabilities and in new markets.”
— Ziv Ofek, MDClone Co-Founder and CEO
“We’ve been looking to invest in the digital health space for a while and were fascinated with MDClone and the immense opportunity it brings to the healthcare system by democratization of healthcare data without the risk of exposing individuals’ data. The company has shown great progress in the past year and an even bigger vision that we believe can transform the way doctors around the world can treat patients and improve care.”
— Eran Westman, General Partner, Viola Growth
